-
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the MORE trialCauley, Jane A. ...Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3 ... years in this placebo-controlled, randomized clinical trial in postmenopausal women with osteoporosis. This article includes results from an additional annual mammogram at 4 years and represents 3,004 additional patient-years of follow-up in this trial. Breast cancers were ascertained through annual screening mammograms and adjudicated by an independent oncology review board. A total of 7,705 women were enrolled in the 4-year trial; 2,576 received placebo, 2,557 raloxifene 60 mg/day, and 2,572 raloxifene 120 mg/day. Women were a mean of 66.5-years old at trial entry, 19 years postmenopause, and osteoporotic (low bone mineral density and/or prevalent vertebral fractures). As of 1 November 1999, 61 invasive breast cancers had been reported and were confirmed by the adjudication board, resulting in a 72% risk reduction with raloxifene (relative risk (RR) 0.28, 95% confidence interval (CI) 0.17, 0.46).These data indicate that 93 osteoporotic women would need to be treated with raloxifene for 4 years to prevent one case of invasive breast cancer. Raloxifene reduced the risk of estrogen receptor-positive invasive breast cancer by 84% (RR 0.16, 95% CI 0.09, 0.30). Raloxifene was generally safe and well-tolerated, however, thromboembolic disease occurred more frequently with raloxifene compared with placebo (p=0.003). We conclude that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after4 years of treatment, through prevention of new cancers or suppression ofsubclinical tumors, or both. Additional randomized clinical trials continue to evaluate this effect in postmenopausal women with osteoporosis, at risk forcardiovascular disease, and at high risk for breast cancer.Source: Breast cancer research and treatment. - ISSN 0167-6806 (Letn. 65, 2001, str. 125-134)Type of material - article, component partPublish date - 2001Language - englishCOBISS.SI-ID - 16643801
Author
Cauley, Jane A. |
Kocijančič, Andreja, 1942-2021
Topics
Breast Neoplasms |
Epidemiology |
Prevention And Control |
Estrogen Antagonists |
Therapeutic Use |
Middle Age |
Aged |
United States |
Ultrasonography, Mammary |
Aged, 80 And Over |
Australia |
Double-Blind Method |
Europe |
Incidence |
New Zealand |
Mammography |
Osteoporosis, Postmenopausal |
Drug Therapy |
Postmenopause |
Dojka, novotvorbe |
Estrogenski antagonisti |
Avstralija |
Dvojnoslepa metoda |
Evropa |
Incidenca |
Mamografija |
Nova Zelandija |
Osteoporoza po menopavzi |
Pomenopavza |
Srednja leta |
Starost 80 in več |
Starostniki |
Ultrasonografija dojke |
ZDA
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Cauley, Jane A. | |
Kocijančič, Andreja, 1942-2021 | 03343 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.